Soleno Therapeutics, Inc.SLNONASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank59
3Y CAGR+136.7%
5Y CAGR-2.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+136.7%/yr
vs -59.7%/yr prior
5Y CAGR
-2.2%/yr
Recent acceleration
Acceleration
+196.5pp
Accelerating
Percentile
P59
Within normal range
vs 5Y Ago
0.9x
Contraction
Streak
3 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 13.72% |
| Q3 2025 | -8.11% |
| Q2 2025 | -32.33% |
| Q1 2025 | -37.09% |
| Q4 2024 | -28.71% |
| Q3 2024 | 144.19% |
| Q2 2024 | -15.48% |
| Q1 2024 | 68.05% |
| Q4 2023 | 43.79% |
| Q3 2023 | 17.55% |
| Q2 2023 | -3.29% |
| Q1 2023 | 39.53% |
| Q4 2022 | 1.03% |
| Q3 2022 | 2.03% |
| Q2 2022 | -7.32% |
| Q1 2022 | 6.80% |
| Q4 2021 | -24.84% |
| Q3 2021 | -11.08% |
| Q2 2021 | -22.01% |
| Q1 2021 | 28.71% |
| Q4 2020 | 15.31% |
| Q3 2020 | -20.91% |
| Q2 2020 | -8.84% |
| Q1 2020 | 26.99% |
| Q4 2019 | 17.42% |
| Q3 2019 | 19.89% |
| Q2 2019 | 35.69% |
| Q1 2019 | 25.91% |
| Q4 2018 | 4.78% |
| Q3 2018 | 22.05% |
| Q2 2018 | 45.25% |
| Q1 2018 | 15.38% |
| Q4 2017 | 4.15% |
| Q3 2017 | 0.82% |
| Q2 2017 | -2.01% |
| Q1 2017 | 4.21% |
| Q4 2016 | -15.67% |
| Q3 2016 | -14.77% |
| Q2 2016 | -25.11% |
| Q1 2016 | 37.98% |